Abstract:
:Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients. Most common options are CyBorD (cyclophosphamide, bortezomib and dexamethasone) and VTD (bortezomib, thalidomide and dexamethasone). Main goal of our retrospective, multicentric study was to compare very good partial response rate (VGPR) or better after induction treatment in a real-world setting in Argentina. Secondary objectives included comparison of complete response (CR) post-induction and after bone marrow transplantation, grade 3-4 adverse events (AEs), progression-free survival (PFS) and overall survival (OS). Three hundred twenty-two patients were included (median age at diagnosis: 57 years; 52% male; 28% had ISS3; 14% with high-risk cytogenetics; median follow up: 34 months). CyBorD was indicated in 74% and 26% received VTD. In VTD arm, 72.62% of patients achieved at least VGPR vs 53.36% receiving CyBorD (odds ratio, OR: 1.96 [95% confidence interval, CI: 1.08-3.57; P = .026] after adjusting by age, ISS [International Staging System], lactate dehydrogenase levels (LDH) and cytogenetic risk. Difference in VGPR was 19.26% (95% CI: 15-24). CR rate were 35.92% (VTD) vs 22.55% (CyBorD) (adjusted OR: 2.13 [95% CI: 1.12-4.05]). Difference in CR was 13.37% (95% CI: 9.6-17.53). Adverse events (AEs) were more common with VTD (69.05% vs 55.46% for CyBorD; P = .030), especially grade 3-4 neuropathy (P = .005) and thrombosis (P = .001). Thromboprophylaxis was inadequate in 20.24% of patients. Hematological AEs were more common with CyBorD, especially thrombocytopenia (P = .017). PFS and OS at 24 months were not different between treatments. In this real-world setting, VTD was associated with better CR and VGPR than CyBorD. Nevertheless, CyBorD continues to be the preferred induction regimen in Argentina, based on safety profile. Frontline autologous stem cell transplantation improves quality of responses, especially in countries with limited access to new drugs.
journal_name
Hematol Oncoljournal_title
Hematological oncologyauthors
Schütz NP,Ochoa P,Duarte P,Remaggi G,Yantorno S,Corzo A,Zabaljauregui S,Shanley C,Lopresti S,Orlando S,Verri V,Quiroga L,García CA,Fernández V,Fantl Ddoi
10.1002/hon.2729subject
Has Abstractpub_date
2020-08-01 00:00:00pages
363-371issue
3eissn
0278-0232issn
1099-1069journal_volume
38pub_type
杂志文章abstract::Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60% to 70% using standard frontline therapy. However, the use of doxorubicin and its cardiotoxicity is a major clinical problem and preexisting cardiac disease may...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2572
更新日期:2019-04-01 00:00:00
abstract::ABCG2 (BCRP) is a member of the ATP-binding cassette (ABC) family of cell surface transport proteins. ABCG2 expression occurs in a variety of normal tissues, and is relatively limited to primitive stem cells. ABCG2 expression is associated with the side population (SP) phenotype of Hoechst 33342 efflux. The substrate ...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.714
更新日期:2003-09-01 00:00:00
abstract::Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070605
更新日期:1989-11-01 00:00:00
abstract::In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level, performing quality control (QC) rounds for follicular lymphoma (FL) and mantle cell lymphoma (MCL) MRD as...
journal_title:Hematological oncology
pub_type: 杂志文章,多中心研究
doi:10.1002/hon.2652
更新日期:2019-10-01 00:00:00
abstract::The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We search...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2192
更新日期:2016-06-01 00:00:00
abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.780
更新日期:2006-09-01 00:00:00
abstract::Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2520
更新日期:2018-10-01 00:00:00
abstract::The elongation factor 1A proteins (eEF1A1/A2) are known to play a role in tumours. We previously found that a more basic isoform of eEF1A (MBI-eEF1A) is present in the cytoskeletal/nuclear-enriched extracts of CCRF-CEM T-lymphoblasts but not in those of normal lymphocytes. To obtain deeper knowledge about MBI-eEF1A bi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2022
更新日期:2013-06-01 00:00:00
abstract::Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular monitoring of BCR-ABL tra...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.792
更新日期:2006-12-01 00:00:00
abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2775
更新日期:2020-10-01 00:00:00
abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析,评审
doi:10.1002/hon.2152
更新日期:2015-09-01 00:00:00
abstract::Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...
journal_title:Hematological oncology
pub_type: 杂志文章,评审
doi:10.1002/hon.2761
更新日期:2020-12-01 00:00:00
abstract::Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2280
更新日期:2017-06-01 00:00:00
abstract::Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.991
更新日期:2011-12-01 00:00:00
abstract::We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900120304
更新日期:1994-05-01 00:00:00
abstract::There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...
journal_title:Hematological oncology
pub_type: 杂志文章,meta分析
doi:10.1002/hon.2015
更新日期:2013-03-01 00:00:00
abstract::Abdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra-abdominal NHL in children with various protocols have not exceeded 54 per cent two-year disease-free survi...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2900090414
更新日期:1991-07-01 00:00:00
abstract::For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...
journal_title:Hematological oncology
pub_type: 临床试验,杂志文章
doi:10.1002/hon.2236
更新日期:2017-03-01 00:00:00
abstract::B-cell post-transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P-PTLD) and monomorphic lymphomas (M-PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD patho...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.859
更新日期:2008-12-01 00:00:00
abstract::Adult T-cell leukemia-lymphoma (ATLL) is a distinct clinicopathologic entity etiologically linked to HTLV-I infection. We have identified five cases of retrovirus-associated ATLL among Hawaii-born first generation offspring (nisei) of migrant Japanese. Four patients were offspring of migrant Japanese (issei) who emigr...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070210
更新日期:1989-03-01 00:00:00
abstract::The management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with singl...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900050207
更新日期:1987-04-01 00:00:00
abstract::We have collected, by an active retrospective survey, all the cases of hematologic malignancies (HM) newly diagnosed during the time period 1974-1993 in the resident population of Sardinia. Diagnosis was deemed valid, after consultation of clinical records, in more than 90% of the 7264 collected cases. The number of n...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.733
更新日期:2004-09-01 00:00:00
abstract::Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2092
更新日期:2014-06-01 00:00:00
abstract::Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed wi...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2378
更新日期:2017-12-01 00:00:00
abstract::The glucose-6-phosphatase (G-6-Pase) enzyme cytochemical reaction was successfully applied on lymph node imprints, after introducing the appropriate modifications related to fixation and to composition of the substrate solutions. Using this method we studied the G-6-Pase cytochemical profile on lymph node imprint prep...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900040403
更新日期:1986-10-01 00:00:00
abstract::Ten patients with the myelodysplastic syndrome (eight with anemia, two with granulocytopenia, four with thrombocytopenia) were given etretinate (ER) and retinoid acid (RA). No correlation was seen between the RA effect in vitro and its clinical effect. No effect was seen of the ER-treatment or of the RA-treatment on a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070407
更新日期:1989-07-01 00:00:00
abstract::Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2647
更新日期:2019-10-01 00:00:00
abstract::The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2811
更新日期:2020-09-26 00:00:00
abstract::To extend the clinical-pathologic description of small cleaved cell lymphoma (SCCL), we reviewed the records of 106 patients with SCCL who were treated in accordance with a policy of watchful waiting and palliative therapy. Median age was 58 years. A pure diffuse pattern was seen in only 16 per cent of cases. Stage II...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2900070506
更新日期:1989-09-01 00:00:00
abstract::Delayed platelet recovery (DPR) despite prompt neutrophil engraftment is frequently observed after allogeneic hematopoietic stem cell transplantation (HSCT). However, few studies have evaluated the risk factors and long-term outcome. Therefore, we retrospectively analysed 219 adult patients who underwent their first a...
journal_title:Hematological oncology
pub_type: 杂志文章
doi:10.1002/hon.2427
更新日期:2018-02-01 00:00:00